Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.

Oncotarget - 30 Jul 2015

Seagle Brandon-Luke L, Eng Kevin H, Dandapani Monica, Yeh Judy Y, Odunsi Kunle, Shahabi Shohreh

Abstract excerpt

The objective of this study was to determine if ovarian cancer patients with a TP53 mutation grouped by location of the mutation within the p53 protein structure exhibit differential survival outcomes. Data from patients with high grade serous ovarian cancer (HGS OvCa) (N = 316) or breast cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Kaplan-Meier Estimate
Share to Neoplasm Grading
Share to Neoplasm Staging

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Outcome Assessment, Health Care

Share to Ovarian Neoplasms

Share to Proportional Hazards Models

Share to Survival Analysis

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 26215675
DOI: 10.18632/oncotarget.4080
PMCID: PMC4621916

Genes

HGS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26215675-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.PMID 26215675Read ↗

Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized TherapeuticsSemantic proximity Read ↗

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.Semantic proximity Read ↗

Pathogenic Genetic Variants From Highly Connected Cancer Susceptibility Genes Confer the Loss of Structural StabilitySemantic proximity Read ↗

TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.Semantic proximity Read ↗

BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients.Semantic proximity Read ↗

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.Semantic proximity Read ↗

Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancerSemantic proximity Read ↗

TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.